Skip to content

    Navin Fluo.Intl.

    NAVINFLUORGood
    Chemicals·30 Jul 2025
    Management Summary

    Navin Fluorine delivered a stellar Q1 FY26 performance with triple-digit growth in EBITDA and PAT, underpinned by strong demand in the HPP and CDMO segments. The company successfully raised ₹750 crores via QIP, enabling an aggressive expansion of its capex framework to ₹1,000 crores annually. Management remains optimistic about sustaining momentum, supported by a solid order book and the commercialization of several high-value projects slated for the coming quarters.

    Highlights

    8

    • Revenue rose 39% YoY to ₹725 crores, driven by robust growth across all three business divisions.

    • Operating EBITDA more than doubled to ₹207 crores, representing a 106% YoY increase.

    • EBITDA margins expanded significantly by 935 bps to 28.5%, compared to 19.5% in Q1 FY25.

    • Net profit (PAT) grew by 129% YoY, reaching ₹117 crores for the quarter.

    • Successfully completed a QIP of ₹750 crores on July 25, 2025, to strengthen the balance sheet and fuel growth.

    • Annual capex guidance expanded to ₹700-1,000 crores from the previous ₹500-600 crores range.

    • R32 project successfully commercialized in March 2025 and is currently running at optimal capacity.

    • AHF project completion is on track for the end of Q2 FY26.

    What Changed2

    vs Q2 FY26

    Tone shiftStrong → GoodGuidance items6 → 5 (-1)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹725 Cr+39%YoY
    2. 02Operating EBITDA₹207 Cr+106%YoY
    3. 03EBITDA Margin28.5%
    4. 04PAT₹117 Cr+129%YoY
    5. 05Operating Cash Flow₹231 Cr

    Segment breakdown

    HPP
    Robust Growth narrative Status100% R32 Utilization
    Specialty Chemicals
    ₹219 Cr Revenue70% Dahej Utilization
    CDMO
    Strong Momentum narrative Status55% Mix (Late Stage)
    List

    Guidance & targets

    5
    CategoryTargetPriority
    Capex
    Annual Capex Framework
    ₹700-1,000 crores
    		High
    Margin
    EBITDA Margin Guidance
    North of 25%
    		Medium
    Capacity
    AHF Project Completion
    End of Q2 FY26
    		High
    Capacity
    cGMP4 Phase 1 Commercialization
    Q3 FY26
    		High
    Revenue
    Nectar Project Revenue Contribution
    ₹300 crores
    		Medium

    Risks & concerns

    4
    RiskSeverity

    Chinese Competition in Agchem

    Intense competition from China continues to exert pressure on pricing in the agrochemical specialty segment. — Management acknowledged

    medium

    US Tariff Uncertainty

    Potential 25% tariff on Indian exports to the US; management believes current ADD coverage limits the impact. — Analyst downplayed

    medium

    Refrigerant Gas Pricing Volatility

    A significant portion of margin expansion (1/3) was driven by a strong pricing environment for R32, which may not be permanent. — Management acknowledged

    medium

    Areas of Evasion(1)

    • Specific revenue asset turns for the Chemours project due to commercial confidentiality.

    Q&A highlights

    3

    “Will we be staking a right to our entitlement, I think the answer is a simple yes. The question is when will we do that? We will do that when we think the discussions are more firmed up with the large customers.”

    Confirms management's intent to aggressively capture market share in the R32 refrigerant gas market as global demand accelerates.

    asked by Sanjesh Jain, ICICI Securities

    2 min read5 chapters

    Detailed Narrative

    01

    HPP Segment Leads Growth with R32 Commercialization

    The High Performance Products (HPP) segment was a primary driver this quarter, following the successful commercialization of the R32 project in March 2025. The facility is already running at optimal capacity, and management is firming up plans with international partners to further expand capacity to meet accelerating global demand. Pricing for repression gases remains firm, contributing roughly one-third of the total margin expansion seen this quarter.

    02

    CDMO Pipeline and cGMP4 Expansion

    The CDMO division continues to show strong momentum with a robust order book for FY26. Phase 1 of the cGMP4 facility expansion is on track for commercialization in Q3 FY26, while Phase 2 (₹128 crores) will be triggered once capacity utilization hits 60%. The company is seeing positive regulatory developments in the US and Europe for its molecules, particularly within the Fermion partnership.

    03

    Strategic Capex Acceleration via QIP

    Following the successful ₹750 crore QIP in July 2025, Navin Fluorine has significantly increased its annual capex guidance to ₹700-1,000 crores. This capital will be deployed to strengthen the balance sheet and fund a 'hopper' of projects currently in the development stage. Management emphasized a disciplined approach, focusing on high-value niche applications rather than commoditized products.

    04

    Specialty Chemicals Recovery and New Molecule Launches

    The Specialty Chemicals division operated at optimal utilization, with the Dahej plant at approximately 70% PAR. The company is set to deliver supplies for three new molecules in Q2 FY26, two of which have significant investment potential. While agchem recovery remains 'flattish to slightly up' due to Chinese competition, the company's focus on new innovative AI intermediates provides a clear growth path.

    05

    Margin Expansion and Operational Leverage

    EBITDA margins reached 28.5%, a massive jump from 19.5% YoY. Management attributed two-thirds of this 935 bps expansion to operating leverage as new assets ramp up, and one-third to the favorable pricing environment. While they maintain a conservative 'north of 25%' guidance for the full year, the current run rate suggests significant upside if pricing remains firm.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.